BRL-26921

The thrombolytic properties of anisoylated plasminogen streptokinase activator complex (BRL 26921) and clinical results of the… (More)

We report the results of two consecutive studies using intravenous bolus injections of streptokinase (SK) or acylated plasminogen… (More)

Fifty patients with a first myocardial infarction presenting within 4 hours of the onset of symptoms were treated with… (More)

The safety and fibrinolytic efficacy of a new anisoylated plasminogen-streptokinase activator complex (APSAC) was tested in 50… (More)

BRL 26921 is a new acylated streptokinase-plasminogen complex which may have a more specific local thrombolytic effect than… (More)

BRL 26921 is a protected plasminogen-streptokinase complex with selective affinity for thrombus. When given intravenously within… (More)

The effects of BRL 26921, an active-site acylated streptokinase-plasminogen complex, on the fibrinolytic and coagulation systems… (More)

The role of thrombus-binding in the fibrinolytic response to the acylated streptokinase.plasminogen activator complex, BRL 26921… (More)

The fibrinolytic efficacy and systemic effects on coagulation variables of intracoronary administration of an acylated… (More)

In view of current interest in the possibility of rapid, high-dose administration of thrombolytic agents by the intravenous route… (More)